Molecule Details
| InChIKey | UCEQXRCJXIVODC-PMACEKPBSA-N |
|---|---|
| Compound Name | Tivantinib |
| Canonical SMILES | O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 4 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 6.94 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB12200 |
|---|---|
| Drug Name | Tivantinib |
| CAS Number | 905854-02-6 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Tivantinib has been investigated in Solid Tumors. |
Categories: Heterocyclic Compounds, Fused-Ring Proto-Oncogene Proteins c-met, antagonists & inhibitors Pyrrolidines
Cross-references: BindingDB: 50146168 ChEBI: 91398 CHEMBL2103882 ChemSpider: 9669218 PDB: TIV PubChem:11494412 PubChem:347828485 Wikipedia: Tivantinib ZINC: ZINC000100016063
Target Activities (4)
| Target | Gene | Organism | Category | Pfam | pChEMBL | Type | Source |
|---|---|---|---|---|---|---|---|
| O60313 | OPA1 | Homo sapiens | Human | PF00350 PF19434 | 7.8 | Kd | ChEMBL |
| P30519 | HMOX2 | Homo sapiens | Human | PF01126 | 6.9 | Kd | ChEMBL |
| O60841 | EIF5B | Homo sapiens | Human | PF00009 PF14578 PF11987 | 6.6 | Kd | ChEMBL |
| P08581 | MET | Homo sapiens | Human | PF07714 PF01437 PF01403 PF01833 | 6.5 | Ki | ChEMBL;BindingDB |
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P08581 | MET | Hepatocyte growth factor receptor | inhibitor | targets |